| Clinical data | |
|---|---|
| Trade names | Oxarol |
| Other names | 22-Oxacalcitriol; OCT |
| Routes of administration | IV or topical |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.212.050 |
| Chemical and physical data | |
| Formula | C26H42O4 |
| Molar mass | 418.618 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Maxacalcitol (trade nameOxarol) is avitamin D3 analog andvitamin D receptor activator (VDRA).[1] As a pharmaceutical drug, it is used as an injection to treatsecondary hyperparathyroidism resulting fromhemodialysis and as a topical ointment forpsoriasis.[2]
It was approved for use in Japan in 2010[3] and in Taiwan in 2018.[4]
Thisdermatologicdrug article is astub. You can help Wikipedia byadding missing information. |